PROGNOSTIC SIGNIFICANCE OF MORPHLOGICAL INVESTIGATION OF PULMONARY TISSUES BIOPSY SAMPLES IN PATIENTS WITH SARCOIDOSIS AND NON-SPECIFIC INTERSTITIAL PNEUMONIA

Abstract

The number of myofibroblasts, the wall thickness of pulmonary arteries of small caliber, and degree of pulmonary fibrosis by Ashcroft scale were assessed in biopsy samples of pulmonary tissue in patients with sarcoidosis and nonspecific interstitial pneumonia. The data obtained were compared with the efficiency of patient therapy with system glucocorticoids. It was found that resistance to steroid therapy in sarcoidosis patients was determined by increase in the number of myofibroblasts in pulmonary tissue, their appearance within interalveolar septa and wasn’t associated with the expression of pulmonary fibrosis and the level of pulmonary diffusion capacity. Hormonal resistance in non-specific interstitial pneumonia correlated to the thickness of pulmonary arteries of small caliber.

About the authors

S. A. Terpigorev

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Author for correspondence.
Email: fake@neicon.ru
Russian Federation

N. A. Korsakova

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Email: fake@neicon.ru
Russian Federation

F. N. Paleyev

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Email: fake@neicon.ru
Russian Federation

L. E. Gurevich

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Email: fake@neicon.ru
Russian Federation

V. A. Ilchenko

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Email: fake@neicon.ru
Russian Federation

References

  1. Борисов С.Е., Соловьева И.П., Евфимьевский В.П. и др. Диагностика и лечение саркоидоза органов дыхания. Пособие для фтизиатров и пульмонологов // Пробл. туберк. 2003. №6. С.51-64.
  2. Саркоидоз: от гипотезы к практике / под ред. А.А. Визе-ля. Казань: ФЭН, 2004. 348 c.
  3. Терпигорев С.А., Сташук Г.А., Дуброва С.Э. Рентгено-логическая семиотика саркоидоза // Клин. мед. 2008. №12. С.13-18.
  4. Abe R., Donnelly S., Peng T. et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites // J. Immunol. 2001. V.166. Р.7556-7562.
  5. Ashcroft T., Simpson J., Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale // J. Clin. Patol. 1988. V.41. Р.467-470.
  6. Baughman R.P., Engel P.J., Taylor L. et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation // Chest. 2010. V.138. Р.1078-1085.
  7. Baughman R.P., Winget D.B., Bowen E.H. et al. Predicting respiratory failure in sarcoid patients // Sarcoid. Vasc. Diffuse Lung Dis. 1997. V.14. P.154-158.
  8. Bonner J. Mesenchimal cell survival in airway and interstitial pulmonary fibrosis // Fibrogenesis Tissue Repair. 2010. No.3. Р.3-15.
  9. Bucala R., Spiegel L.A., Chesney J. et al. Circulating fibrocytes define a new leukocytes population, that mediates tissue repair // Molecular Med. 1994. V.1. P.71-81.
  10. Hashimoto N., Jin H., Liu T. et al. Bone marrow-derived progenitor cells in pulmonary fibrosis // Clin. Invest. 2004. V.113. P.243-252.
  11. Kisseleva T., Brenner D. Mechanisms of fibrogenesis // Experim. Biol. Med. 2002. V.233, No.2. 2008. P.109-122.
  12. Lamberto C., Nunes H., Toumelin Ph. et al. Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis // Chest. 2004. V.125. P.2061-2068.
  13. Larsen K., Tufvesson E., Malmstrom J. et al. Presence of activated mobile fibroblasts in bronchoalveolar lavage from patients with mild asthma // Am. J. Resp. Crit. Care Med. 2004. V.10. P.1049-1056.
  14. Laurent G., McAnulty R., Hill M., Chambers R. Multiple mechanisms for fibroblast activation in pulmonary fibrosis // Proc. Am. Torac. Soc. 2008. V.5. P.311-315.
  15. Lynch J., Ma Y., Koss M., White E. Pulmonary sarcoidosis // Seminars in respiratory and critical care medicine. 2007. V.28. P.53-74.
  16. Nagai S., Handa T., Ito Y. et al. Outcome of sarcoidosis // Clin. Chest. Med. 2008. V.29, No.3. P.565-574.
  17. Nicholson A.G., Gibbs A.R., Addis B.J. et al. Interobserver variation in diffuse parenchymal lung disease // Thorax. 2004. V.59. P.500-505.
  18. Nunes H., Uzunhan Y., Freynet O. et al. Pulmonary hypertension associated with sarcoidosis // Eur. Respir. Monogr. 2012. V.57. P.166-181.
  19. Olson A.L., Wigris J.J., Lezotte D.C. et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003 // Am. J. Respir. Crit. Care Med. 2007. V.176. P.277-284.
  20. Phillips R., Burdick M., Hong D. et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis // J. Clin. Invest . 2004. No.3. P.438-446.
  21. Ryu J.H., Daniels C.E., Hartman T.E. et al. Diagnosis of interstitial lung diseases // Mayo Clin. Proc. 2007. P.939-943.
  22. Sheehan R.E., Walls A.U., Millie D.G., Hansell D.M. Nitrafurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities // J. Comput. Ass. Tomogr. 2000. V.24. P.259-261.
  23. Westergren-Thorsson G., Hernnas J., Sarnstrand B. et al. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats // J. Clin. Invest. 1993. V.92. P.632-637.
  24. Xu M., Deng B., Chow Y. et al. Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone // J. Ethnopharmacol. 2007. V.112, No.2. P.292-299.
  25. Yaekashiwa M., Nakayama S., Ohnuma K. et al. Simultaneous or delayed administration of hepatocyte growth factor equally regresses the fibrotic changes in murine lung injury induced by bleomycin // Am. J. Respir. Crit. Care Med. 1997. V.156, No.6. P.1937-1944

Copyright (c) 2016 Terpigorev S.A., Korsakova N.A., Paleyev F.N., Gurevich L.E., Ilchenko V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies